Global Oncology Drugs Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Global Oncology Drugs Market 2025 by Company, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Oncology Drugs market size was valued at US$ 225860 million in 2024 and is forecast to a readjusted size of USD 438600 million by 2031 with a CAGR of 10.1% during review period.

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.



When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.



Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.



Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.

The industrys leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.

This report is a detailed and comprehensive analysis for global Oncology Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Oncology Drugs market size and forecasts, in consumption value ($ Million), 2020-2031

Global Oncology Drugs market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global Oncology Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031

Global Oncology Drugs market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Oncology Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Oncology Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Oncology Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Chemotherapy

Targeted Therapy

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Others

Market segment by Application

Blood Cancer

Breast Cancer

Gastrointestinal Cancer

Prostate Cancer

Respiratory or Lung Cancer

Others

Market segment by players, this report covers

Roche

Celgene

Novartis

Bristol-Myers Squibb

Johnson & Johnson

Merck & Co.

AstraZeneca

Pfizer

Amgen

Eli Lilly

AbbVie

Takeda

Astellas

Ipsen

Sanofi

Bayer

Biogen Idec

Teva

Otsuka

Eisai

Merck KGaA

Gilead Sciences

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Oncology Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Oncology Drugs, with revenue, gross margin, and global market share of Oncology Drugs from 2020 to 2025.

Chapter 3, the Oncology Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Oncology Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Oncology Drugs.

Chapter 13, to describe Oncology Drugs research findings and conclusion.